Peptide YY (PYY) Research Guide 2026: NPY Pathway, Anorexigenic Mechanism, and COA Specification

Product Deep Dive | 2026-07-09 | 9 min read

A 2026 research guide to Peptide YY (PYY): NPY receptor pharmacology, anorexigenic mechanism, PYY1-36 vs. PYY3-36 isoforms, synthesis and COA specification for laboratory researchers.

What is Peptide YY and why it matters for metabolic research

Peptide YY (PYY) is a gut-derived satiety hormone that has attracted increasing research attention as the metabolic field moves beyond GLP-1 monotherapy. Native PYY is released from L-cells in the ileum and colon within 15 minutes of food intake and signals fullness to the hypothalamus via NPY receptors. The truncated form, PYY3-36, is the primary anorexigenic isoform and is being explored both as a standalone therapy and as an add-on to GLP-1 agonists.

NPY receptor pharmacology

PYY acts through three NPY receptors:

| Receptor | PYY Isoform Affinity | Primary Location | Effect | | --- | --- | --- | --- | | Y1 | High (PYY1-36) | Hypothalamus, vasculature | Vasoconstriction, appetite suppression | | Y2 | High (PYY3-36) | Hypothalamus, hippocampus | Presynaptic autoinhibition, satiety | | Y5 | Moderate | Hypothalamus | Food intake regulation |

The key pharmacological distinction:

  • **PYY1-36** activates Y1 and Y2 receptors broadly
  • **PYY3-36** is Y2-selective after DPP-4 cleavage and crosses the blood-brain barrier more readily

Y2 receptor activation in the arcuate nucleus inhibits NPY neurons (reducing appetite) and is the primary target for anorexigenic effects.

Amino acid sequences

PYY1-36 (Human): H-Tyr-Pro-Ala-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2

PYY3-36 (Human): H-Ala-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2

PYY3-36 is 34 amino acids. The N-terminal Tyr-Pro is removed by DPP-4 cleavage, changing the receptor selectivity profile.

Synthesis considerations

PYY is a linear 36-mer (or 34-mer for PYY3-36) with no disulfide bonds, making SPPS straightforward relative to larger GLP-1 analogs. Key considerations:

  • **DPP-4 sensitivity** — PYY1-36 is rapidly cleaved to PYY3-36 in vivo. This is both a research consideration (DPP-4 inhibitor can be used to study the intact form) and a formulation challenge.
  • **Aggregation tendency** — PYY can aggregate at high concentrations; use dilute solutions for in vivo work
  • **Acetate salt form** — most research PYY is supplied as the acetate salt

Research applications

Obesity and satiety research

  • Acute food intake studies in rodents
  • Hypothalamic signaling pathway analysis (Y2 receptor, NPY circuit)
  • Combination with GLP-1 analogs (additive anorexigenic effects)

Combination therapy rationale PYY3-36 and GLP-1 agonists have complementary mechanisms:

  • GLP-1 acts primarily on the upper GI tract (gastric emptying, early satiety)
  • PYY3-36 acts on the distal gut and hypothalamus (postprandial fullness, sustained satiety)

Phase 1 combination data with PYY3-36 + GLP-1 showed greater caloric intake reduction than either agent alone.

Metabolic disease models

  • Diet-induced obesity (DIO) mouse/rat models
  • High-fat diet studies
  • NPY receptor knockout studies
  • Hypothalamic-pituitary-adrenal axis studies

COA specification for PYY research peptide

| Test | Method | Acceptance Criterion | | --- | --- | --- | | Appearance | Visual | White to off-white lyophilized powder | | HPLC Purity | RP-HPLC, 220nm | ≥95% | | MS (ESI) | Mass spectrometry | ±0.5% of theoretical m/z | | Endotoxin | LAL kinetic chromogenic | <1.0 EU/mg | | Water content | KF titration | <3% | | Residual solvents | GC headspace | Within ICH Q3C limits |

For PYY3-36, verify the mass corresponds to the 34-residue form, not the 36-residue parent.

Sourcing

PYY1-36 and PYY3-36 are both available as research peptides from qualified manufacturers. The key verification is MS confirmation of the correct sequence (36 vs. 34 amino acids) and HPLC purity ≥95%.

ZePeptide supplies both PYY1-36 and PYY3-36 for laboratory research with full COA documentation and validated cold-chain packaging.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides